Neuland Laboratories Ltd.
Snapshot View

View in App

Prices View details >>

1629.75 +1.30 ▲0.1%

21 March 2023, 04:01:00 PM
Volume: 2,603

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.neulandlabs.com
Market Cap 2,096.66 Cr.
Enterprise Value(EV) 2,269.81 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 78.53 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 20.81 Trailing Twelve Months Ending 2022-12
Industry PE 31.71 Trailing Twelve Months Ending 2022-12
Book Value / Share 715.96 Trailing Twelve Months Ending 2022-12
Price to Book Value 2.28 Calculated using Price: 1,634.20
Dividend Yield 0.31 Period Ending 2022-03
No. of Shares Subscribed 1.28 Cr. 12,829,889 Shares
FaceValue 10
Company Profile
Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients. Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+0.08%
1 Week
-1.69%
1 Month
-0.14%
3 Month
-1.72%
6 Month
+32.12%
1 Year
+40.54%
2 Year
-17.10%
5 Year
+127.21%
10 Year
+1740.69%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 24.14 11.24 15.64 22.34 5.02 3.48 2.30 10.79 7.85
Return on Capital Employed (%) 18.99 15.75 18.57 15.98 4.07 3.99 7.85 12.81 9.44
Return on Assets (%) 5.89 3.20 5.23 6.65 1.23 1.49 1.37 6.31 4.71

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 124 161 187 546 558 699 710 786 841 883
Non Curr. Liab. 52 55 69 54 146 104 163 170 180 164
Curr. Liab. 307 295 268 286 367 327 358 369 363 378
Minority Int. 0 0
Equity & Liab. 483 512 524 886 1,071 1,130 1,231 1,325 1,383 1,424
Non Curr. Assets 196 196 210 511 624 677 716 775 801 805
Curr. Assets 288 316 314 375 447 453 515 550 583 620
Misc. Exp. not W/O
Total Assets 483 512 524 886 1,071 1,130 1,231 1,325 1,383 1,424

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 466 469 510 579 527 667 763 937 951 1,040
Other Income 3 1 2 1 5 3 4 16 2 2
Total Income 469 470 512 580 532 670 767 953 953 1,042
Total Expenditure -395 -403 -430 -473 -477 -608 -661 -790 -808 -849
PBIDT 74 67 82 108 55 62 106 163 145 193
Interest -25 -27 -24 -21 -19 -16 -22 -18 -14 -12
Depreciation -15 -15 -16 -19 -22 -26 -31 -40 -49 -52
Taxation -8 -9 -15 -20 -2 -4 -37 -25 -18 -29
Exceptional Items
PAT 27 16 27 47 12 16 16 81 64 101
Minority Interest 0 0 0
Share Associate
Other Related Items
Consolidated Net Profit 27 16 27 47 12 16 16 81 64 101
Adjusted EPS 33 18 31 53 14 13 13 63 50 78

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 26 49 13 45 39 11 70 57 189 59
Cash Fr. Inv. -7 -10 -14 -20 -42 -116 -77 -49 -84 -94
Cash Fr. Finan. -20 -39 1 -24 0 105 12 -5 -114 38
Net Change -1 0 0 1 -4 0 5 3 -9 3
Cash & Cash Eqvt 1 1 1 2 3 3 8 11 2 5

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 36.25 36.22 36.22 36.22 36.22 36.22 36.22 36.22 36.14
Public 63.75 63.78 63.78 63.78 63.78 63.78 63.78 63.78 63.86
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 4.30 4.30 4.30 4.30 4.30 0.00 0.00 0.00 0.00

Announcements View Details >>

Sat, 18 Feb 2023
Intimation Of S&P Global ESG Score 2022
We would like to inform that in our first endeavour to evaluate our environmental social and governance (ESG) efforts our Company was awarded an ESG score of 48 out of 100 by S&P Global. The Companys score placed it in the 92nd percentile among 343 companies considered as industry peers during 2021 and 2022. The average ESG score in the said category during the defined period was 21.Neuland is committed to integrating sustainability and ESG priorities across its operations.
Fri, 17 Feb 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Earnings call conducted on February 14 2023
Tue, 14 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication Q3 FY23 financial results

Technical Scans View Details >>

Mon, 20 Mar 2023
Opening at High Opening at High
High Increase in 6 Months High Increase in 6 Months
High Increase in 1 Year High Increase in 1 Year
High Increase in 5 Years High Increase in 5 Years
Closing Near 100 SMA Closing Near 100 SMA

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 230,636.07 956.20 -0.5%
Divi's Laboratories Ltd. 74,303.33 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. 73,967.90 4,419.30 -0.5%
Cipla Ltd. 70,000.14 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. 61,905.77 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. 51,514.78 1,518.00 -0.3%
Zydus Lifesciences Ltd. 48,165.73 477.95 +0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 54.76 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-12 31.06 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 20.25 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-12 26.53 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 80.95 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 61.90 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-12 23.34 477.95 +0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.17 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-12 5.98 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.35 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-12 3.08 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 10.04 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.07 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.79 477.95 +0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 0.04 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 477.95 +0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 13.10 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 477.95 +0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 13.10 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 477.95 +0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 477.95 +0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 477.95 +0.4%

FAQ's On Neuland Laboratories Ltd.

What is Neuland Laboratories share price?
Can I buy Neuland Laboratories shares now?
What is the Dividend Yield of Neuland Laboratories?
What is the Market Cap of Neuland Laboratories?
What are the key metrics to analyse Neuland Laboratories?
What is the 52 Week High and Low of Neuland Laboratories?
What is the trend of Neuland Laboratories share price?